Show simple item record

dc.contributor.authorBoscolo-Rizzo, Paolo
dc.contributor.authorD'Alessandro, Andrea
dc.contributor.authorPolesel, Jerry
dc.contributor.authorBorsetto, Daniele
dc.contributor.authorTofanelli, Margherita
dc.contributor.authorDeganello, Alberto
dc.contributor.authorTomasoni, Michele
dc.contributor.authorNicolai, Piero
dc.contributor.authorBossi, Paolo
dc.contributor.authorSpinato, Giacomo
dc.contributor.authorMenegaldo, Anna
dc.contributor.authorCiorba, Andrea
dc.contributor.authorPelucchi, Stefano
dc.contributor.authorBianchini, Chiara
dc.contributor.authorCazzador, Diego
dc.contributor.authorRamaciotti, Giulia
dc.contributor.authorLupato, Valentina
dc.contributor.authorGiacomarra, Vittorio
dc.contributor.authorMolteni, Gabriele
dc.contributor.authorMarchioni, Daniele
dc.contributor.authorFabbris, Cristoforo
dc.contributor.authorOcchini, Antonio
dc.contributor.authorBertino, Giulia
dc.contributor.authorFussey, Jonathan
dc.contributor.authorTirelli, Giancarlo
dc.description.abstract<h4>Background</h4>Inflammatory blood markers have been associated with oncological outcomes in several cancers, but evidence for head and neck squamous cell carcinoma (HNSCC) is scanty. Therefore, this study aims at investigating the association between five different inflammatory blood markers and several oncological outcomes.<h4>Methods</h4>This multi-centre retrospective analysis included 925 consecutive patients with primary HPV-negative HNSCC (median age: 68 years) diagnosed between April 2004 and June 2018, whose pre-treatment blood parameters were available. Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), systemic inflammatory marker (SIM), and systemic immune-inflammation index (SII) were calculated; their associations with local, regional, and distant failure, disease-free survival (DFS), and overall survival (OS) was calculated.<h4>Results</h4>The median follow-up was 53 months. All five indexes were significantly associated with OS; the highest accuracy in predicting patients' survival was found for SIM (10-year OS = 53.2% for SIM < 1.40 and 40.9% for SIM ≥ 2.46; c-index = 0.569) and LMR (10-year OS = 60.4% for LMR ≥ 3.76 and 40.5% for LMR < 2.92; c-index = 0.568). While LMR showed the strongest association with local failure (HR = 2.16; 95% CI:1.22-3.84), PLR showed the strongest association with regional (HR = 1.98; 95% CI:1.24-3.15) and distant failure (HR = 1.67; 95% CI:1.08-2.58).<h4>Conclusion</h4>Different inflammatory blood markers may be useful to identify patients at risk of local, regional, or distant recurrences who may benefit from treatment intensification or intensive surveillance programs.
dc.rightsAttribution 4.0 International
dc.sourcenlmid: 100967800
dc.sourceessn: 1471-2407
dc.subjectHead And Neck Cancer
dc.subjectOverall Survival
dc.subjectLocal Recurrence
dc.subjectBlood Markers
dc.subjectInflammatory System
dc.subjectHead and Neck Neoplasms
dc.subjectInflammation Mediators
dc.subjectBlood Cell Count
dc.subjectHealth Status Indicators
dc.subjectRisk Assessment
dc.subjectRetrospective Studies
dc.subjectMiddle Aged
dc.subjectBiomarkers, Tumor
dc.subjectSquamous Cell Carcinoma of Head and Neck
dc.titleDifferent inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study.
prism.publicationNameBMC cancer
dc.contributor.orcidBoscolo-Rizzo, Paolo [0000-0002-4635-7959]
dc.contributor.orcidPolesel, Jerry [0000-0001-9381-1520]

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International